Teclison
Clinical-stage biotechnology company developing therapies for solid tumors that combine tumor-targeted, hypoxia-activated agents delivered by transarterial embolization with immune checkpoint inhibitors to induce tumor necrosis, remodel the tumor immune microenvironment, and generate systemic antitumor immunity. The company conducts preclinical and early clinical studies, engages with regulatory authorities, and collaborates with external pharmaceutical and clinical partners.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Hypoxia-activated agent delivered via transarterial embolization (TATE platform)
Tumor-targeted therapeutic approach delivered by transarterial embolization to create tumor hypoxia that activates a locally delivered agent, intended to induce tumor necrosis and stimulate systemic antitumor immunity when combined with immune checkpoint inhibitors.
Tumor antigen-presenting agent for solid tumors
Therapeutic designed to induce tumor cell death and promote presentation of tumor antigens to the immune system to trigger antitumor immune responses across multiple solid tumor types.
Immune response amplifying agent for post-treatment activation
Agent intended to be used following primary tumor-targeting treatments to harness the physiological immune response and amplify targeting against multiple tumor antigens.
TATE platform therapy
A transarterial embolization therapy that induces complete tumor necrosis in intermediate-stage liver cancer patients, resulting in significantly improved survival compared to standard of care.
Hypoxia-activated agent delivered via transarterial embolization (TATE platform)
Tumor-targeted therapeutic approach delivered by transarterial embolization to create tumor hypoxia that activates a locally delivered agent, intended to induce tumor necrosis and stimulate systemic antitumor immunity when combined with immune checkpoint inhibitors.
Tumor antigen-presenting agent for solid tumors
Therapeutic designed to induce tumor cell death and promote presentation of tumor antigens to the immune system to trigger antitumor immune responses across multiple solid tumor types.
Immune response amplifying agent for post-treatment activation
Agent intended to be used following primary tumor-targeting treatments to harness the physiological immune response and amplify targeting against multiple tumor antigens.
TATE platform therapy
A transarterial embolization therapy that induces complete tumor necrosis in intermediate-stage liver cancer patients, resulting in significantly improved survival compared to standard of care.
Services
Co-development and clinical collaboration with pharmaceutical companies and academic centers to evaluate combination regimens and support multi-center trials.
Co-development and clinical collaboration with pharmaceutical companies and academic centers to evaluate combination regimens and support multi-center trials.
Expertise Areas
- Solid tumor immunotherapy development
- Tumor microenvironment modulation
- Interventional radiology-based drug delivery
- Clinical trial management and biostatistics
Key Technologies
- Hypoxia-activated prodrugs
- Transarterial embolization (intra-arterial delivery)
- Macrophage polarization modulation
- Immune checkpoint inhibitor combination strategies
News & Updates
Interview and discussion about approaches to trigger systemic immune responses following local tumor therapies.
Podcast interview discussing use of tumor hypoxia to activate drug and induce tumor cell death.
Recognition by the Journal of Vascular and Interventional Radiology for a distinguished clinical study.
Completed a financing round to advance solid-tumor development programs.
Interview and discussion about approaches to trigger systemic immune responses following local tumor therapies.
Podcast interview discussing use of tumor hypoxia to activate drug and induce tumor cell death.
Recognition by the Journal of Vascular and Interventional Radiology for a distinguished clinical study.
Completed a financing round to advance solid-tumor development programs.